Safety, Efficacy, and Long-Term Follow-Up Evaluation of Perioperative Epirubicin, Cisplatin, and Capecitabine Chemotherapy in Esophageal Resection for Adenocarcinoma

Annals of Surgical Oncology

Volumn 22, Issue 5, 2015, Pages 1555-1563

  van der Sluis, P C ^a   Ubink, I ^a   van der Horst, S ^a   Boonstra, J J ^b   Voest, E E ^a   Ruurda, J P ^a   Borel Rinkes, I H M ^a   Wiezer, M J ^b   Schipper, M E I ^a   Siersema, P D ^a   Los, M ^b   Lolkema, M P ^a   van Hillegersberg, R ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; EPIRUBICIN;

ADENOCARCINOMA; ADULT; AGED; CANCER STAGING; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW UP; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERIOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDY; SAFETY; STOMACH NEOPLASMS; SURVIVAL RATE; TIME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CISPLATIN; COMBINED MODALITY THERAPY; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PERIOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SAFETY; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 84939932997     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4120-9     Document Type: Article

References (25)

1. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Eng J Med. 2002;347:1662–9.
2. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992–1000.
3. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.
4. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979–84.
5. Urba SG, Orringer MB, Turrisi A, et al.: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–13.
6. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659–68.
7. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
8. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
9. Starling N, Okines A, Cunningham D, et al. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin, and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer. 2009;100:1725–30.
10. Verhage RJ, van der Horst S, van der Sluis PC, Lolkema MP, van Hillegersberg R. Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma. Ann Surg Oncol. 2012;19:684–92.
11. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda:National Cancer Institute; 2006.
12. Sobin LH, Gospodarowicz MK, Wittekind CH, eds. TNM classification of malignant tumors. 7th ed. Wiley-Blackwell, Oxford; 2009.
13. Verhage RJ, Zandvoort HJ, ten Kate FJ, van Hillegersberg R. How to define a positive circumferential resection margin in T3 adenocarcinoma of the esophagus. Am J Surg Pathol. 2011;35:919–26.
14. Schnetzler B, Popova N, Collao Lamb C, et al. (2001) Coronary spasm induced by capecitabine. Ann Oncol. 12:723–5.
15. Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest. 2009;27:105–15.
16. Van Custem E, Hoff PM, Blum JL et al. Incidence of cardiotoxicity with oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13:484–5.
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
18. Brewster DH, Fraser LA, McKinney PA, Black RJ. Socioeconomic status and risk of adenocarcinoma of the oesophagus and cancer of the gastric cardia in Scotland. Br J Cancer. 2000;83:387–90.
19. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology. 1998;115:50–7.
20. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998;58:588–90.
21. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2:28–37.
22. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.
23. Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, Barbour AP, Gotley DC, Smithers BM. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47:354–60.
24. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.
25. van Hagen P, Wijnhoven BP, Nafteux P, Moons J, Haustermans K, De Hertogh G, van Lanschot JJ, Lerut T. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. Br J Surg. 2013;100:267–73.